Business
Sotera Health Reports Fourth-Quarter and Full-Year 2024 Results; Provides 2025 Outlook
2024 net revenues increased 4.9% to $1.10 billion, compared to 2023; or 5.4% on a constant currency basis2024 net income of $44 million or $0.16 per diluted
About this update from Sotera Health Company
[{"type":"text","content":"2024 net revenues increased 4.9% to $1.10 billion, compared to 2023; or 5.4% on a constant currency basis2024 net income of $44 million or $0.16 per diluted share, compared to 20232024 Adjusted EBITDA(1) increased 3.9% to $549 million, compared to 2023; or 4.6% on a constant currency basis2024 Adjusted EPS(1) of $0.70, a decrease of $0.02 per diluted share, compared to 2023Full-year 2025 outlook of 4.0% - 6.0% net revenues growth and 4.5% - 6.5% Adjusted EBITDA growth, both on a constant currency basis CLEVELAND, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the fourth-quarter and full-year 2024 and its initial 2025 outlook. For the fourth-quarter 2024, net revenues decreased 6.5% to $290 million, compared with $310 million in the same period a year ago, as expected. Net revenues decreased 5.2% on a constant currency basis. Net income attributable to the Company (“net income”) was $12 million, or $0.04 per diluted share, compared with net income attributable to the Company of $39 million, or $0.14 per diluted share for the fourth-quarter 2023. Adjusted EBITDA decreased by 8.3% to $153 million compared to the prior-year quarter. Adjusted EBITDA decreased 6.7% on a constant currency basis. Adjusted earnings per diluted share (“Adjusted EPS”) was $0.21, a decrease of $0.02 per diluted share, compared to the fourth quarter of 2023. For full-year 2024, net revenues increased 4.9% to $1.10 billion, compared with $1.05 billion for full-year 2023. Net revenues increased 5.4% on a constant currency basis. Net income was $44 million, or $0.16 per diluted share, compared with net income of $51 million, or $0.18 per diluted share, for 2023. Adjusted EBITDA increased 3.9% to $549 million, compared to 2023. Adjusted EBITDA increased 4.6% on a constant currency basis. Adjusted EPS was $0.70 in 2024, a decrease of $0.02 from 2023. “I am pleased to announce another year of top- and bottom-line growth in 2024. This marks the 19th consecutive year of annual revenue growth for the company,” said Chairman and Chief Executive Officer, Michael B. Petras, Jr. “We accomplished several important milestones during th...